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ABSTRACT We have recently shown that antibody-
induced blockade of C5a, C5a receptors, or IL-17A
greatly reduced the harmful outcomes of sepsis. In the
current study, normal cardiomyocytes from young (300
g) male Sprague-Dawley rats responded in vitro to C5a
(ED5055 nM) with release of IL-6 and TNF, peaking
between 2 to 8 h. Neutralizing antibodies to mouse C5a
or IL-17A (ED5040 g for each, based on improved
survival) reduced spontaneous in vitro release of car-
diosuppressive cytokines and chemokines in cardiomy-
ocytes obtained from mice with polymicrobial sepsis. A
non-neutralizing C5a antibody had no such effects.
Cardiomyocytes from septic mice (C57Bl/6) showed
increased mRNA for TNFR1, IL-6 (gp80), and C5aR at
6 h after sepsis. Cardiomyocytes from septic C5aR/
or C5L2/ mice did not show spontaneous in vitro
release of cytokines and chemokines. These data sug-
gest that cardiomyocytes from septic mice release sup-
pressive cytokines in a C5a-, C5aR-, and IL-17A-depen-
dent manner, followed by mediator reactivity with
receptors on cardiomyocytes, resulting in defective
contractility and relaxation. These data may be relevant
to a strategy for the treatment of heart dysfunction
developing during sepsis.—Atefi, G., Zetoune, F. S.,
Herron, T. J., Jalife, J., Bosmann, M., Chen, A., Al-Aref,
R., Sarma, J. V., Ward, P. A. Complement dependency
of cardiomyocyte release of mediators during sepsis.
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There is generally accepted evidence that humans
in sepsis often exhibit a hyperdynamic cardiovascular
state that is associated with biventricular dilatation,
high cardiac output, and reduced systemic vascular
resistance (1, 2). Such responses appear to be reversible
if survival occurs, with little or no evidence of residual
structural damage to the heart (3, 4). There are sug-
gestions that sepsis in humans and in animals is linked
to the presence of circulating cytokines (TNF, IL-1,
and IL-6) that have cardiosuppressive effects, defined
by their in vitro ability to cause defective contractility
and relaxation of cardiomyocytes (CMs) (5). There are
at least 3 hypotheses to explain heart dysfunction in
sepsis: loss of energetic function in CMs due to defec-
tive electron transport in mitochondria, resulting in
inadequate levels of ATP (reviewed in refs. 6–9); circu-
lating and, perhaps, intracardiac cytokines causing im-
pairment of CM contractility and relaxation (10–16);
and complement activation during sepsis, resulting in
generation of the powerful anaphylatoxin C5a, which
can react with its receptor, C5aR, on CMs to induce
defects in CM contractility and relaxation (4, 17–19).
Following sepsis in rodents and humans or acute
thermal trauma in rodents, there is accumulating evi-
dence for the presence of cardiosuppressive cytokines
in serum, which, when added in vitro to CMs, results in
defects in contractility and relaxation. In the case of
septic human serum, such effects have been indirectly
linked to the presence of TNF, IL-1, IL-6, and IL-10
(11–13). TNF and IL-1 have been shown to impair
contractility of electrically stimulated human atrial
heart strips (12), while repetitive subcutaneous injec-
tion of IL-6 into rats causes heart dilatation and re-
duced cardiac output (13). Suppression of rat CM
contractility can be induced by TNF, IL-1, or human
septic shock serum, with reversal of CM dysfunction in
the copresence of TGF (14). In rodents exposed to
acute thermal injury of skin or after infusion of endo-
toxin (LPS), CMs released TNF that was associated
with NFB activation (16). There have been sugges-
tions that there may be synergy in the copresence of
different cardiosuppressive cytokines (12). Such data
suggest that sepsis, burn injury, and endotoxemia cause
the appearance of cardiosuppressive cytokines in serum
and that under certain conditions, CMs may produce
and release similar cytokines that could interact with
receptors on CMs, causing defects in contractility and
relaxation.
We have recently reported that in cecal ligation and
puncture (CLP)-induced sepsis in rats, there are pro-
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found contractility defects in CMs that seem to be
linked to the presence of C5a interacting with its
receptor, C5aR. C5aR is up-regulated on CMs following
CLP (17). C5a interaction with C5aR on normal CMs in
vitro resulted in substantial defects in CM contractility
and relaxation. Such responses were exaggerated when
CLP CMs were used. Furthermore, when C5a was
blocked in vivo with neutralizing antibody in CLP rats,
CMs from these animals demonstrated no defects in
vitro in spontaneous contractility or relaxation (17). In
the current study, we show that CLP CMs contain and
release cardiosuppressive cytokines in a C5a-, IL-17A-,
and C5aR-dependent manner, suggesting a possible
linkage between these molecules and the ensuing car-
diac dysfunction of sepsis.
MATERIALS AND METHODS
Experimental animals
Specific pathogen-free, 8- to 9-wk-old male wild-type (WT)
mice (Jackson Laboratories, Bar Harbor, ME, USA), C5/
and C5/ mice (congenic strains B10.D2/oSn and B10.D2/
nSn; Jackson Laboratories), C5aR/, and C5L2/ mice
(breeding stock from Dr. C. Gerard, Boston Children’s Hos-
pital, Boston, MA, USA) were used. All mice were on a
C57BL/6 background. Young adult male Sprague-Dawley rats
(Harlan, Indianapolis, IN, USA) weighing 300 g were used
where indicated. Animals were housed in a specific pathogen-
free environment and allowed to acclimate to their surround-
ings for 1 wk prior to use. Standard mouse and rat chow and
water were available to animals during the course of the
experiment. All experiments were performed in accordance
with the guidelines set forth by the U.S. National Institutes of
Health for care and use of animals. Approval for experimen-
tal protocol was obtained from the University Committee on
Use and Care of Animals at the University of Michigan
Medical School.
Sepsis model and antibodies employed
Intraperitoneal injections of ketamine and xylazine were used
for anesthesia and analgesia. Experimental sepsis was induced
using the moderately severe form of CLP, as described
elsewhere (18). Briefly, after an abdominal midline incision,
the cecum was exposed, ligated (involving 75% total cecum),
and punctured through and through with a 21-gauge needle.
A small portion of feces was expressed through the puncture
sites. After repositioning of the bowel, the abdomen was
closed in layers using surgical sutures (Ethicon Inc., Somer-
ville, NJ, USA) and metallic clips. Before and after the
surgery, animals had unrestricted access to food and water.
To induce the intermediate-grade CLP, 40% of the cecum
was ligated. All mice received fluid resuscitation (1.0 ml
lactated Ringer’s solution), which was given subcutaneously
every 12 h starting at the time of sham surgery or CLP, for a
total of 48 h. Some mice received an intravenous infusion at
the time of CLP of 40–50 g preimmune rabbit IgG, anti-C5a
affinity-purified IgG, or rat mAb to mouse IL-17A. As indi-
cated, the rabbit affinity-purified IgG to C5a was directed
toward the C-terminal peptide region of C5a (residues 58–
77) or toward the N-terminal region (residues 1–16). These
antibodies were reactive with both rat and mouse C5a (19,
20). The affinity-purified IgG antibody against the C-terminal
region was neutralizing for C5a, but this was not the case for
the IgG antibody to the N-terminal region of C5a. Details of
these antibodies are provided elsewhere (19, 20). In CLP
mice, the ED50 (providing 50% survival) for the antibody to
the C-terminal peptide of C5a was 40 g i.v. (administered at
the time of CLP; ref. 20), while all CLP mice given preim-
mune rabbit IgG were dead before d 3 (20). The rat neutral-
izing mAb to mouse IL-17A was purchased from eBioscience
(San Diego, CA, USA). The ED50 of this antibody in CLP mice
was 50 g i.v., producing 50% survival 5 d after CLP, whereas
only 10% of mice survived when given a control mouse IgG
(21). Finally, 80–90% CLP mice that received 40 g i.v. of
affinity-purified IgG to the N-terminal region of C5a, which is
a non-neutralizing antibody to C5a, were dead by 72 h (19).
Mice were sacrificed by abdominal aortic exsanguination at 6,
12, 24, and 48 h after CLP.
CM isolation and responses to C5a
CMs were isolated from left ventricular walls of rats (Sprague
Dawley, young adult males, 300 g) using a commercial kit
(Adumyts Cardiomyocyte Isolation Kit, Cellutron Life Tech-
nology, Highland Park, NJ, USA) according to the manufac-
turer’s instructions. Rats were treated with anticoagulant (500
U heparin i.p.) 30 min before heart isolation. Exsanguination
was induced by transection of the distal abdominal aorta.
Thereafter, 5.0 ml sterile HBSS was injected into the left
ventricle in order to clear blood from the aorta and its
tributaries. The heart was removed and placed in ice-cold
HBSS. The heart was then placed in a 5.0 ml A1 solution, and
the ventricles were finely minced with surgical scissors. The
minced tissue in A1 solution was then incubated at 37°C for
12 min on a gentle shaker. Then, the minced tissue was
allowed to settle, and the supernatant fluid was gently aspi-
rated. Thereafter, 5.0 ml A2 solution (containing hyaluroni-
dase and collagenase II) was added to the minces and the
tubes placed on a shaker for 10 min at 37°C. Thereafter,
the minced tissue was subjected to centrifugation at 800 g.
The supernatant fluids were gently aspirated, and 1.0 ml
solution A3 was added to the pellets. Following this, 5.0 ml of
the A3 solution was admixed, and the tissue was incubated on
a shaker for 10 min at room temperature, followed by
centrifugation. These steps were repeated 5 times. The
minced tissue was finally suspended in 0.5 ml (mouse) or 5.0
ml (rat) HBSS. CMs were counted in a hemocytometer. The
number of CMs used for a given experiment is described in
Results. In another set of experiments, mouse CMs from 25-g
C57Bl/6/J mice were isolated as indicated above. In such
cases there were 10-fold reductions in units of heparin
employed (30 U) and 5-fold reductions in volume (0.5 ml) of
solutions (A1, A2, and A3) employed.
Preparation of mouse CMs
CLP or sham-operated mice were treated with the anticoag-
ulant heparin sodium (250 U i.p.). After 15 min, mice were
deeply anesthetized using ketamine and xylazine, and hearts
were immediately exposed via median sternotomy. Heart
perfusion was initiated via the right ventricle by injecting 10
ml Kerbs-Henseleit buffer (containing, in mM: 118 NaCl, 4.7
KCL, 21 NaHCO3, 1.8 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, and 11
glucose, pH 7.40), supplemented with 5 mM 2-aminoethane-
sulfonic acid (taurine) and calcium (1.2 mM). The solution
was injected into the right ventricle, and thence into the
pulmonary arteries and finally into the systemic circulation.
Blood and perfusion fluid were drained from the inferior
vena cava. Hearts were then rapidly removed and placed in
4°C Kerbs-Henseleit buffer without calcium, rinsed, and
2501MEDIATOR RELEASE FROM SEPTIC CARDIOMYOCYTES
dissected into small pieces. CM isolation was performed using
the Cellutron kit. Then CMs were filtered through a 100-m
cell strainer (Fisher Scientific, Pittsburgh, PA, USA) and
incubated with 5 ml of 6% BSA-KHB containing 300 M, 600
M, and 1.2 mM calcium for 45 min (15 min for each calcium
concentration). CMs were counted using a hemocytometer.
CMs with rod-like shapes with clearly defined and sharp
striations were counted, whereas cells with membrane bleb-
bing, loss of striations, or rounded cells were not counted.
Cell suspensions with viability of 75% were used for all
subsequent experiments. The purity of CM suspensions and
possible contamination with leukocytes was assessed with
Giemsa staining, using cytospin preparations (data not
shown). Subsequently, cells were cultured in 6-well (3.5-cm
diameter) tissue culture plates (at 37°C, 5% CO2) in medium
(2 ml of medium containing 5	104 CMs/well) supplied by
Cellutron containing antibiotic-antimycotic (Invitrogen,
Carlsbad, CA, USA) overnight. The supernatant fluids were
analyzed by ELISA for mediators.
Plasma collection
Whole blood was collected by abdominal aortic puncture
using 1.0 ml syringes containing anticoagulant citrate dex-
trose (ACD; Baxter, Deerfield, IL, USA) in a 9:1 (blood/
ACD) ratio at different time points after CLP. Samples were
centrifuged (2000 rpm, 10 min, 4°C); plasma was obtained
and immediately stored at 80°C until further analysis.
RNA isolation and detection of C5aR, C5L2, IL-6R and
TNFR mRNA in CMs by real-time quantitative PCR
analysis
Mouse hearts were obtained 0, 6, 12, and 24 h after CLP or
sham procedure (laparotomy only), and CMs were isolated as
described earlier. Total RNA was isolated using the TRIzol
method (Life Technologies, Carlsbad, CA, USA) according to
the manufacturer’s instructions. Digestion of any contaminat-
ing DNA was achieved by treatment of samples with RNase-
free DNase (Promega, Madison, WI, USA). Reverse transcrip-
tion was performed with 1 g RNA using TaqMan Reverse
Transcription Reagents (Applied Biosystems, Carlsbad, CA,
USA) according to the manufacturer’s protocol. Real-time
PCR was performed with primers as indicated below and in
Niederbichler et al. (17).
Primers for C5aR: forward, 5
 -GAAGCGGCAAC-
CTGGGGATGT-3
; reverse, 5
-CGTCTGGCTCGAAGGCTGT-
CAC-3
. Primers for C5L2: forward, 5
-CTGGGCCTCTTGCT-
GACTGTGC-3
; reverse, 5
-GCCCCAGGAAGCCAAAGAGGA-3
.
Primers for TNFRI: forward, 5
-GCTGACCCTCTGCTCTACGAA-
3
; reverse, 5
-GCCATCCACCACAGCATACA-3
. Primers for IL-6
receptor (gp80): forward, 5
-CCAACCACGAAGGCTGTGCT-3
; re-
verse, 5
-GCTCCACTGGCCAAGGTCAA-3
. Primers for house-
keeping gene GAPDH: forward, 5
-TACCCCCAATGTGTC-
CGTCGTG-3
; reverse, 5
-CCTTCAGTGGGCCCTCAGATGC-3
.
Real-time PCR reactions were prepared in duplicate with a
50 l reaction using PCR Master Mix SYBR Green (Applied
Biosystems). A 30-min incubation at 48°C was followed by a
“hot start” for 10 min (at 95°C), 40 cycles being used for
amplification with a melting temperature of 95°C (15 s) and
an annealing/extending temperature of 60°C (1 min), follow
by melting curve generation starting at 60°C with a gradual
increase in the temperature to 95°C in 0.2°C steps. An
amplification plot was generated using 2-fold dilution of the
cDNA generated from a known (1 g) of mRNA. The cycle
threshold (CT) was set above the baseline fluorescence.
Plotting the log dilution vs. CT value generated a standard
curve. Quantification of C5aR, C5L2, IL-6R (gp80), TNFR1,
and GAPDH in the sample was determined using standard
curves. Purity of the products was assessed by generating
melting curves. Furthermore, the PCR products were run out
on the 1% gel to confirm that the amplicons generated were
single bands at the expected size (unpublished data). The
C5aR, C5L2, IL-6R (gp80), TNFR1 ratio to GAPDH was then
plotted for the various time points in CLP and sham-treated
mice. Real-time PCR was performed using the 7500 real-time
PCR system (Applied Biosystems). CT values, standard curves,
and melting curves were generated using the software pro-
vided by the manufacturer (Applied Biosystems).
Heart homogenate protocol
Hearts from mice were harvested, rinsed, and trimmed of fat
and atria in Krebs-Henseleit buffer without calcium and kept
at 4°C. Each heart was then homogenized in 1.2 ml of RIPA
lysis buffer (Upstate, Temecula, CA, USA), which contained a
protease inhibitor cocktail (Roche, Indianapolis, IN, USA),
until no large tissue pieces were present (1 min). The
homogenates were kept on ice for 15 min, and then sonicated
for 10 s (using a Branson sonicator, power setting 4, 40% duty
level; Branson Ultrasonics, Danbury, CT, USA). Samples were
centrifuged at 12,000 g for 10 min, and the supernatants
obtained were stored immediately at 80°C until further
analysis.
Cytokine/chemokine measurements
CMs and plasma samples were collected as described above.
Mouse ELISA kits (R&D Systems, Minneapolis, MN, USA)
were used to measure IL-1, TNF, IL-6, MIP-1, and MIP-2.
The mediators MCP-1, KC, IL-10, and IL-1 were measured by
ELISA using the Bio-Plex 200 System (Bio-Rad, Hercules, CA,
USA). Measurements were performed according to the man-
ufacturer’s protocols.
Statistical analysis
All values are expressed as means  se. Data were analyzed
with a 1-way ANOVA, and individual group means were then
compared with a Student-Newman-Keuls test. Differences
were considered significant at values of P  0.05.
RESULTS
Features of isolated CMs and CLP hearts
Figure 1A shows the typical morphology of isolated
CMs, demonstrating a CM from a sham-treated rat
heart, the features of which have been described else-
where (22). Immunostaining was performed with pri-
mary antibody against -actin and Texas Red-conju-
gated secondary antibody, revealing the repetitive
pattern of actin protein. Such CMs demonstrate spon-
taneous contractions (not shown). Figure 1B shows the
time course for release of IL-6 in sham-treated rat CMs
(2	106) exposed to 100 nM recombinant rat (rr) C5a
for various periods of time. Release of IL-6 peaked at
2 h following addition of 100 nM C5a and persisted
through the 8-h interval. At 24 h of incubation with
C5a, IL-6 levels had fallen back to baseline levels. Figure
1C, D features CMs (2	106) from sham-treated rat
hearts responding to rr C5a (8 h incubation at 37°C) in
2502 Vol. 25 July 2011 ATEFI ET AL.The FASEB Journal  www.fasebj.org
a dose-dependent manner (ED5055 nM), with pro-
gressive release of TNF and IL-6. Release of TNF
appeared to peak between 80–100 nM C5a; in the case
of IL-6, peak release followed a similar pattern. Figure
1E represents immunostaining of frozen sections of rat
hearts, featuring sham-treated CMs at 	25 (Fig. 1E1–3)
and CLP hearts 24 h after CLP at 	100 (Fig. 1E4, 5). At
0 h (Fig. 1E1), no staining for TNF was found when
the secondary antibody was omitted. Frozen sections of
sham-treated CLP hearts revealed constitutive staining
for TNF (Fig. 1E2) and, at higher resolution (	100),
intense cytoplasmic staining for TNF in hearts 24 h
after CLP (Fig. 1E4). The striations indicate that
TNF was present within CMs. Constitutive staining
for IL-1 revealed cytoplasmic granular and cytoplas-
mic staining in sham-treated hearts (Fig. 1E3) and
more intense granular and cytoplasmic staining in
CMs of CLP hearts (at 24 h; Fig. 1E5). Similar results
were obtained for IL-6 (data not shown). Accord-
ingly, CLP was associated with accentuated presence
of cytokines in CMs.
Time courses for mediator presence in mouse
plasma, heart homogenates and CM culture fluids
after CLP
As indicated in the introduction, the literature fre-
quently emphasizes IL-1, TNF, and IL-6 as cardiosup-
pressive cytokines. However, a series of other cytokines
and chemokines were also studied in the context of
CLP, since many are proinflammatory mediators
thought to have adverse effects in the setting of the
cytokine storm. In plasma (Fig. 2) and in heart homog-
enates (Fig. 3) from CLP mice, a consistent pattern
emerged in which cytokines and chemokines peaked at
24 h after CLP, followed by a decline at 48 and 72 h. In
heart homogenates, TNF was present in very low
amounts compared to other mediators (Fig. 3). Medi-
ator levels were higher in plasma than in heart homog-
enates, but this may be an artifact, since mediator levels
in heart homogenates were expressed as picograms per
gram total protein. It is possible that some contribu-
tions from contaminating inflammatory cells could
have occurred in the homogenates. Figure 4 shows that
spontaneous mediator release from cultured CMs ob-
tained from CLP WT mice occurred as early as 8–12 h
after CLP, with peak release at 24 h, followed by a drop
to baseline levels 48 h after CLP. Once again, TNF
levels in supernatant fluids were very low but showed a
similar time course in which the peak was at 24 h after
CLP.
Increased mRNAs for cytokine and C5a receptors in
mouse CMs after CLP
Since IL-6, TNF, and IL-1 have been designated as
cardiosuppressive cytokines (12, 14–16), it is possible
that their release from CLP CMs results in a positive
feedback, with released cytokines reacting with upregu-
lated receptors on surfaces of CMs. As shown in Fig. 5,
mRNA expression was measured in control WT mouse
CMs obtained before CLP and 6, 12, and 24 h after
CLP. Real-time PCR was used. As shown in Fig. 5A,
mRNA for mouse C5aR rose almost 3-fold by 6 h after
CLP and then fell back to baseline by 12 h, while mRNA
for C5L2 showed a very small increase (nonsignificant)
Figure 1. A) Normal rat CM immunostained with primary antibody
against -actin and Texas-Red conjugated secondary antibody. B) Time
course for release of IL-6 from rat CMs (2	106) exposed to 100 nM
recombinant rat C5a at 37°C. C, D) Dose responses for sham rat CMs
(2	106) incubated with HBSS (none) or recombinant rat C5a (40–100
nM) for 12 h at 37°C, following which supernatant fluids were
evaluated by ELISA for TNF (C) and IL-6 (D). For each bar, n  5.
E) Frozen sections of rat heart obtained before CLP (panels 1–3) or
24 h after CLP and stained for TNF (panel 4) or IL-1 (panel 5). In
panel 1, the primary antibody (to TNF) was omitted.
2503MEDIATOR RELEASE FROM SEPTIC CARDIOMYOCYTES
at 6 h, falling back to basal levels (Fig. 5B). In the case
of IL-6R (gp80), like the data for C5aR (Fig. 5A),
mRNA levels peaked at 6 h after CLP and fell back to
basal levels 12 and 24 h after CLP (Fig. 5C), while
mRNA for TNFR1 was elevated 6 h after CLP and
persisted 12 and 24 h after CLP (Fig. 5D). The up-
regulation of C5aR, IL-6R, and TNFR1 following CLP
could set the stage for cytokine release from CMs, as a
result of autocrine/paracrine interaction of mediators
with upregulated CM receptors, in a manner that could
further accentuate the release of cardiosuppressive
cytokines from CMs. Alternatively, interaction of cyto-
kines with upregulated receptors on CLP CMs might
activate signaling pathways that cause contractility and
relaxation of CMs.
Requirements for C5a receptors, C5a, and IL-17A for
cytokine/chemokine release from CLP CMs
These studies were performed using CMs from WT and
various knockout (KO) mice (all on a C57Bl/6 back-
ground) 24 h after CLP, at which time there was a peak
in spontaneous in vitro release of cytokines and chemo-
kines from CMs (Fig. 4). The data in Fig. 6 show the
effects of the presence or absence on/in CMs of C5aR
or C5L2 on spontaneous mediator release from CMs
(24 h after CLP) as compared to release from WT CMs
under similar conditions. For each of the 8 mediators
evaluated, there were global reductions in KO
(C5aR/, C5L2/) CMs, with mediator levels falling
to levels found in sham-treated CMs (Fig. 6), suggesting
that mediator release is dependent on the combined
Figure 2. Presence of cytokines and chemokines in plasma from sham-treated and WT mice at 12, 24, 48, and 72 h after CLP.
A) IL-6. B) TNF. C) IL-1. D) MIP-1. E) MIP-2. F) MCP-1. G) KC. H) IL-10. For each bar, n  5.
Figure 3. Presence of cytokines and chemokines in heart homogenates from sham-treated and WT mice at 12, 24, 48, and 72 h
after CLP. A) IL-6. B) TNF. C) IL-1. D) MIP-1. E) MIP-2. F) MCP-1. G) KC. H) IL-10. Data are expressed as amount of
mediator (pg/ml) per gram total protein. For each bar, n  5.
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engagement of both C5aR and C5L2. Even the anti-
inflammatory mediator, IL-10, fell to baseline levels in
C5a receptor KO CMs (Fig. 6H). These data are remi-
niscent of effects of dual blockade or absence in vivo of
C5L2 and C5aR in CLP mice, in which plasma levels of
cytokines and chemokines after CLP were almost abol-
ished compared to effects of single-receptor blockade
or absence of C5a receptors (4, 10, 18, 20, 21). Such
data are consistent with the concept that mediator
release from CMs after CLP is dependent on combined
and perhaps sequential engagement of C5aR and
C5L2. Other patterns of note in Fig. 6 suggest that the
least abundant cytokines and chemokines released
from WT CLP CMs are TNF, IL-1, and IL-10, each
being produced in amounts  70 pg/ml, while other
products (IL-6, MIP-1, MIP-2, MCP-1, and KC) were
produced in amounts 250 pg/ml.
In Fig. 7, CMs were obtained from WT mice that had
undergone sham surgery or CLP 24 h earlier. As
indicated, mice were treated at the time of CLP with 50
g i.v. control IgG vs. the same amount of rat neutral-
izing mAb to mouse IL-17A (23) or 40 g affinity-
purified rabbit anti-mouse C5a directed against the
C-terminal region (as described above and in ref. 21).
The IC50 values for anti-C5a and anti-IL-17A IgG for
enhanced survival after CLP were 40 g for each
antibody. Neutralization of IL-17A greatly improved
survival in CLP WT mice and profoundly depressed the
cytokine storm in plasma. WT CLP CMs (2	106 at 24 h)
were incubated in vitro at 37°C for 18 h to assess
spontaneous release of mediators. The supernatant
fluids were subsequently analyzed for cytokines (TNF
and IL-6) and chemokines (MIP-1 and MIP-2). As
shown in Fig. 7A, TNF levels were low in supernatant
fluids from sham-treated CMs (13 pg/ml) and only
doubled in CMs from CLP (24 h) mice treated with
normal IgG. In vivo treatment of WT CLP mice with
anti-C5a (neutralizing IgG reactive with the C-terminal
region) modestly reduced TNF release (nonsignifi-
cant); anti-IL-17A had no effect on TNF release from
CLP CMs, but the amount of TNF released was very
low. However, treatment of mice with either neutraliz-
ing antibody to C5a or IL-17A caused IL-6 levels to drop
to baseline levels (Fig. 7B). Anti-C5a reduced MIP-1
release from CLP CMs, while anti-17A also caused
reductions to baseline levels (Fig. 7C). The pattern for
MIP-2 release (Fig. 7D) was very similar to that for
MIP-1 (Fig. 7C). Collectively, the data suggest that in
vivo neutralization of either C5a or IL-17A reduces in
vitro release of cytokines and chemokines from CLP
CMs, with the exception of limited effects on TNF
release, similar to what we have noted before when
plasma levels of TNF were evaluated after CLP in WT
mice were treated with either anti-C5a or antibodies to
C5aR or C5L2 (20). Precisely how C5a and IL-17A
enhance cytokine and chemokine release from CLP
CMs remains to be determined, and whether they act in
sequence has not been evaluated. In data not shown, 50
g affinity-purified non-neutralizing rabbit IgG (reac-
tive with the N-terminal region of C5a) and a neutral-
izing IgG (reactive with the C-terminal region of C5a)
were employed immediately after CLP induction in WT
C57Bl/6 mice. The non-neutralizing antibody had no
inhibitory effects on mediator release, while the neu-
tralizing antibody caused 73, 56, and 95% reductions in
release of IL-6, MIP-1, and MIP-2, respectively.
DISCUSSION
As indicated above, there is evidence in both human
sepsis and experimental sepsis (such as endotoxemia,
infusion of live Escherichia coli, or CLP) that complement
activation is occurring, followed by the cytokine storm,
which is defined by the presence of numerous proinflam-
matory cytokines and chemokines in plasma. This event
often evolves into multiorgan failure, although the extent
Figure 5. mRNA expression based on real-time PCR for C5a
receptors (C5aR, C5L2), IL-6R (gp80) and TNFR1, in sham-
treated (control) WT mouse hearts and in hearts at 6, 12, and
24 h following CLP. A) C5aR. B) C5L2. C) IL-6R. D) TNFR1.
For each bar, n  3 separate samples.
Figure 4. Release of mediators from sham-treated or CLP WT
CMs obtained at 8, 12, 24, and 48 h after CLP. A) IL-6. B)
TNF. C) MIP-1. D) MIP-2. CMs were cultured for 18 h at
37°C. For each bar, n  5.
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to which the presence of numerous proinflammatory
mediators in plasma can be directly linked to organ injury
and failure is not clear. In the case of IL-1, TNF, and
IL-6 (as well as IL-8 in humans), these cytokines have been
described as having cardiosuppressive effects. The term
cardiosuppressive refers to the fact that these cytokines,
when added in vitro to CMs, cause reversible contractile
and relaxation defects. Such evidence has been obtained
by the use of recombinant cytokines, as well as by neutral-
ization or removal of cytokines from septic human sera (5,
11–15). In the current report, sham-treated rat CMs
responded to C5a in vitro in a dose-dependent manner
(Fig. 1), resulting in release of proinflammatory cytokines
(TNF and IL-6). CMs obtained from CLP-treated ro-
dents spontaneously released a variety of proinflamma-
tory cytokines and chemokines in vitro (Fig. 4). There
appears to be a linkage between C5a, C5a receptors
(C5aR and C5L2), and IL-17A and spontaneous release in
vitro of cytokines and chemokines from CLP CMs based
on in vivo blockade of C5a or IL-17 and the use of C5a
receptor-KO mice (Figs. 6, 7). Up-regulation in CLP CMs
of receptors (for C5a, TNF, and IL-6; Fig. 5) might
potentiate the autocrine/paracrine effects of cytokines
released from CLP CMs, based on mediator release de-
scribed in Figs. 4 and 6–8. After in vivo blockade (neu-
tralization) of C5a or IL-17A, in vitro release of cytokines
and chemokines from CLP mouse CMs was dramatically
reduced except for TNF, which was present at very low
levels (Fig. 7). Release of TNF and IL-1 was low (20 and
9 pg/ml, respectively) as compared to IL-6 and other
proinflammatory cytokines and chemokines, which were
released in much higher quantities (100–1000 pg/ml;
Fig. 6). These data suggest that the presence of C5a and
IL-17A is necessary for full release of mediators from CLP
CMs (Fig. 7). The role of IL-17A in the cytokine storm
after CLP has been documented recently, based on in vivo
neutralization of IL-17A in CLP WT mice (21). This
resulted in profound reductions in plasma levels of pro-
inflammatory cytokines and chemokines and increased
levels of the anti-inflammatory cytokine IL-10. Such data
suggest, in the setting of CLP, that C5a and IL-17A are
upstream “master switches” that govern the cytokine
storm. Our current data demonstrate release of a variety
of proinflammatory cytokines and chemokines from CMs
obtained from CLP mice. Such release occurred in a
manner that also required availability of both C5aR and
C5L2 (Fig. 6). Collectively, these findings suggest that
maximal mediator release from CMs after CLP requires
IL-17A as well as C5a and both C5a receptors. These
findings may have a parallel with our recent study in
which optimal survival in CLP mice required absence or
blockade of both C5aR and C5L2, which resulted in
ablation of the cytokine storm (20). Such data indicate
that development of the cytokine storm requires engage-
ment of both C5aR and C5L2, perhaps in a sequential
manner.
Figure 8 shows an overview of the findings presented
in the current report. It appears that CLP activates
Figure 6. Release of mediators from CMs obtained from WT mice before (sham) and 24 h after CLP, as well as from CLP
mice that were C5aR/ or C5L2/. A) IL-6. B) TNF. C) IL-1. D) MIP-1. E) MIP-2. F) MCP-1. G) KC. H) IL-10. For
each bar, n  5.
Figure 7. Cytokines (TNF, IL-6) and chemokines (MIP-1,
MIP-2) released from sham-treated mouse CMs and from 24 h
CLP CMs obtained from WT mice administered control IgG,
anti-C5a (40 g), or anti-IL-17A IgG (50 g), all administered
i.v. at time 0. A) TNF. B) IL-6. C) MIP-1. D) MIP-2.For each
bar, n  5.
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complement systemically, resulting in generation of
C5a, which interacts with C5aR (and perhaps C5L2) on
CMs to bring about contractility defects and develop-
ment of heart failure (17). In parallel, C5a interactions
with C5aR and C5L2 on CMs cause release from CMs of
TNF and IL-6. Simultaneously, up-regulation of recep-
tors on CLP CMs occurs, including C5aR, TNFR1, and
IL-6R (Fig. 5). This would allow positive feedback
interaction of released cytokines with their receptors
on CMs, resulting in contractility and relaxation de-
fects. Whether C5a independently reacts directly with
C5aR (and perhaps C5L2) to cause electrophysiological
defects or has effects on CMs that are linked to release
of cardiosuppressive cytokines from CMs remains to be
determined. It might be noted that ischemic injury to
the heart activates gene machinery that results in
production of a host of complement proteins that may
set the stage for a complement storm in the myocar-
dium (23). Such data suggest that, under certain con-
ditions, CMs can express complement proteins that can
ultimately produce complement activation products,
C5a and C5b-9, both of which have been linked to
cardiac dysfunction after acute ischemic injury (4, 17,
23–25). We have recently suggested that once a patho-
logical process is triggered in the heart, its outcomes
may be greatly amplified by C5-derived complement
activation products locally generated (24).
As indicated above, reversible cardiac dysfunction
clearly occurs after sepsis in both humans and animals.
The basis for this complication is debatable. Some
possibilities are described above. Loss of CM ATP levels
has been associated with activation of the DNA repair
enzyme poly(adenosine diphosphate-ribose) polymer-
ase (PARP), which results in consumptive depletion of
ATP (26). Loss of mitochondrial ATP may be linked to
broad cellular dysfunction that is commonly seen in the
shock syndrome. Since there is evidence that heart
tissue obtained from autopsy specimens from humans
with sepsis shows the presence of activated PARP (26),
this could cause ATP depletion, leading to the onset of
mitochondrial energetic dysfunction in the heart in
sepsis. Inhibition of PARP has been described to be
cardioprotective after acute myocardial ischemia (27).
Our own group has demonstrated that CLP in mice and
rats leads to C5a generation and up-regulation of C5aR
on CMs (Fig. 5 and refs. 17, 20). Blockade of C5a with
neutralizing antibody was highly protective in the set-
ting of CLP (28) and prevented the development of
defects in both contractility and relaxation of CMs (17).
Furthermore, since sham-treated CMs constitutively
express C5aR, in vitro addition of C5a to CMs induced
defects in contractility and relaxation (17). Finally,
cardiosuppressive cytokines have been described by
several groups in the context of sepsis or endotoxemia.
These cytokines cause development of contractile de-
fects in CMs. Such cytokines may be serum derived or
directly produced in the heart and include TNF, IL-6,
and IL-1 (Fig. 1 and as described above). Others have
suggested that, at least in human septic serum, IL-6,
IL-8, and IL-10 may be important cardiosuppressive
factors (11). On the basis of such reports, addition of
any of these recombinant cytokines to sham-treated
CMs in vitro will induce contractile defects. It seems
highly likely that under such conditions cardiosuppres-
sive cytokines may affect CM function via interaction
with cytokine receptors on CMs. Furthermore, some
reports suggest that neutralization or removal of these
cytokines reduces the adverse effects of septic serum on
CMs (see above). The accumulating evidence that CLP
CMs release a variety of cytokines and chemokines,
together with evidence that cardiosuppressive cytokines
can be released from CMs after endotoxemia or acute
burn injury of skin (29, 30), suggests that intramyocar-
dial production of such cytokines may result in self-
inflicted harm to the heart during sepsis. This could be
referred to as a myocardial cytokine storm. Obviously,
the plethora of cytokines with cardiosuppressive effects
suggests that targeting individual cytokines for block-
ade will not likely be an effective strategy for preventing
or treating cardiac dysfunction in sepsis as related to
cytokines. Rather, targeting one of the master switches
of cytokine expression in sepsis (C5a or IL-17A)
or relevant receptors may be a more efficacious
intervention.
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